New SOL-1 post-hoc analyses presented at VBS reinforce AXPAXLI’s unmatched durability in wet AMD with sustained disease controlAXPAXLI ...
New SOL-1 post-hoc analyses presented at VBS reinforce AXPAXLI's unmatched durability in wet AMD with sustained disease control AXPAXLI demonstrated robust CSFT control with a median time of 39 weeks ...
The Social Empowerment Agency (SEA) recently launched its annual Child Abuse Awareness And Prevention Month with a stark ...
George O. Waring IV, MD, FACS, discussed how “tolerance” may expand the QRS functional vision model, with new data on IOL ...
In the United States, ONS-5010/LYTENAVA™ (bevacizumab-vikg) is investigational. If approved in the United States, ONS-5010/LYTENAVA™, would be the first approved ophthalmic formulation of bevacizumab ...
Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of ...
5don MSN
Donald Trump Health Update: Unsteady Walk, Hand Bruise & Melania Moment Spark Dementia Debate
A viral clip of Donald Trump holding Melania Trump while descending steps has sparked fresh health concerns and online debate ...
Explore 25 Rare Skills Only 1% of Humans Have, from hyperthymesia to super recognizers. Discover extraordinary human ...
Johnson & Johnson will present data from two major studies supporting the performance of its recently FDA-approved TECNIS PureSee intraocular lens (IOL) at the 2026 American Society of Cataract and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results